Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

PURPOSE: Rapalogs are allosteric mTOR inhibitors and approved agents for advanced kidney cancer. Reports of clonal heterogeneity in this disease challenge the concept of targeted monotherapy, yet a small subset of patients derives extended benefit. Our aim was to analyze such outliers and explore th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Voss, Martin H., Hakimi, A. Ari, Pham, Can G., Brannon, A. Rose, Chen, Ying-Bei, Cunha, Luis F., Akin, Oguz, Liu, Han, Takeda, Shugaku, Scott, Sasinya N., Socci, Nicholas D., Viale, Agnes, Schultz, Nikolaus, Sander, Chris, Reuter, Victor E., Russo, Paul, Cheng, Emily H., Motzer, Robert J., Berger, Michael F., Hsieh, James J.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4140619/
https://ncbi.nlm.nih.gov/pubmed/24622468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2345
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars